Janux Therapeutics Inc

NASDAQ JANX

Data sourced from

and

Download Data

Janux Therapeutics Inc Net Working Capital to Total Assets Ratio 3 year CAGR for the quarter ending March 31, 2024: 1.55%

Janux Therapeutics Inc Net Working Capital to Total Assets Ratio 3 year CAGR is 1.55% for the quarter ending March 31, 2024. The net working capital to total assets ratio measures the proportion of a company's net working capital (current assets minus current liabilities) to its total assets. It is calculated by dividing the net working capital by the total assets. This ratio indicates the percentage of a company's total assets that are financed by its net working capital. A higher ratio suggests a greater reliance on working capital to fund the company's operations and indicates a potential liquidity cushion. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Janux Therapeutics Inc Net Working Capital to Total Assets Ratio for the quarter ending March 31, 2023 was 0.86, a -9.46% change year over year.
Janux Therapeutics Inc Net Working Capital to Total Assets Ratio for the quarter ending March 31, 2022 was 0.96, a 6.36% change year over year.
Janux Therapeutics Inc Net Working Capital to Total Assets Ratio for the quarter ending March 31, 2021 was 0.90.

NASDAQ: JANX

Janux Therapeutics Inc

CEO	Dr. David Alan Campbell Ph.D.
IPO Date	June 11, 2021
Location	United States
Headquarters	11099 North Torrey Pines Road, La Jolla, CA, United States, 92037
Employees	68
Sector	Healthcare
Industry	Biotechnology

Description

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Key trends